Pharmacotherapeutic Challenges in Parkinson’s Disease Inpatients by Lertxundi, Unax et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12
Pharmacotherapeutic Challenges in Parkinson’s Disease
Inpatients
Unax Lertxundi, Rafael Hernández,
Saioa Domingo-Echaburu,
Javier Peral-Aguirregoitia and Juan Medrano
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62561
Abstract
During the natural history of Parkinson’s disease (PD), many patients require hospital
admission for medical or surgical problems other than the motor features of PD. Therefore,
they are often admitted to non-neurological wards where the staff is unfamiliar with PD
management. Among the issues related to hospitalization in patients with PD, drug-
related problems such as inappropriate levodopa timing of administration, the use of
contraindicated, centrally acting antidopaminergic drugs and anticholinergic burden
remain among the most troublesome.
Keywords: Parkinson’s disease, antidopaminergic, levodopa, inappropriate prescrip‐
tion, antipsychotic
1. Introduction
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease known to occur
primarily from middle age to later in life [1]. The frequency of PD varies depending on the
diagnostic criteria, study population, and is estimated to be 0.3% of the entire population, about
1–2% in people over 60–65 years [1] and 3–5% in people 85 years and older [2, 3]. It is a com‐
mon progressive and disabling neurological disorder characterized by the degeneration of
several different neuronal populations that lead to the cardinal features of PD, which are tremor,
bradykinesia, rigidity and postural instability [4].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
During the natural history of the disease, many patients require hospital admission for medical
or surgical problems other than the motor features of PD. As a consequence, they are often
admitted to non-neurological wards where staff is unfamiliar with PD management, as it is
generally managed in the outpatient setting [5, 6]. The problems and complications faced by
PD patients while in hospital have urged specialists to develop specific guidelines [7]. Among
the issues related to hospitalization in PD patients, drug-related problems remain amongst the
most troublesome [8, 9]. In this chapter we will review some of them, such as inappropriate
levodopa timing administration, centrally acting antidopaminergic drug administration and
anticholinergic burden.
2. Inappropriate inpatient levodopa administration
Management of medication regimens increases in complexity as PD progresses, frequently
leading to prescriptions taken six or more times per day. Besides, dosing intervals are specific
to each individual patient. Although adequate anti-PD medication management is essential
during hospital admissions (regarding drugs, dosages and specific dosage schedules), its
management is frequently described as suboptimal, leading to adverse clinical sequelae.
One of the first studies about the problem came from a retrospective study of patients with PD
hospitalized in the United Kingdom [10]. In that report, an alarming percentage of patients
admitted to the hospital had critical medications stopped or omitted. Even more worryingly,
of these around 60% experienced significant adverse effects, including the need to transfer a
patient to the intensive care unit. In another study carried out in surgical wards of a Scottish
hospital, three out of four hospitalized patients with PD did not receive their medications on
time or had had doses entirely omitted [11]. In the same line, in a small study we conducted
in Alto Deba hospital (in the Basque Country, Spain) we found that chronic anti-PD prescrip‐
tion was omitted in 12/73 admissions [12].
In a survey of National Parkinson Foundation Center, the majority of the participating centers
were not confident that medication schedules were adhered to during hospital stays, per‐
haps because the importance of medication timing in PD was not well understood by hospital
staff [13]. Again, from a patient perspective, a survey carried out by a Dutch team showed that
incorrect medication distribution contributed to intrahospital deterioration [14].
The same Dutch team published a prospective study that showed that medication error was
the most important risk factor for deterioration [15]. More recently, a cross-sectional chart
review carried out in 339 consecutive hospital encounters from 212 PD subjects in Florida has
shown that patients who had delayed administration or missed at least one dose stayed
longer [16].
Skelly et al. [17], in a study carried out in the Royal Derby Hospital in the United Kingdom
(National Parkinson Foundation Centre of Excellence for Parkinson’s Disease), reported that
2.5% of all doses were not administered because the drug was not available on time. It has to
be remarked that this happened in a ward specially designed to treat patients with PD, with
Challenges in Parkinson's Disease246
an enhanced stock of anti-PD medications [17]. We consider that this problem is likely to be
aggravated in other non-specialized wards and especially in smaller hospitals.
Figure 1. The importance of on-time levodopa administration.
To counteract this difficulty, Parkinson’s United Kingdom “Get it on time campaign” [18],
(Figure 1) among others [19], advices that all commercially available antiparkinsonian drugs
should be timely available in all hospital wards. Given the data described previously, we find
this unfeasible, especially in small hospitals where the availability of all the anti-PD drugs
would certainly result in the expiration of many of these drugs before they could be used. May
be a reasonable solution can be found in Skelly et al.’s own final considerations: “The availa‐
ble stock was not used as flexibly as we had hoped: e.g. doses of modified release medications were omitted
rather than a temporary switch to available standard release drugs.”
The Institute for Safe Medication Practices (ISMP) has recently issued a generic recommenda‐
tion that, whereas undoubtedly helpful, will result insufficient. Their recommendation
specifically states “avoiding non-formulary delays ensuring that your formulary provides common
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PD medications and doses so that drug administration is not delayed while the pharmacy obtains non-
formulary medications” [20]. Based on the available data, we have recently proposed an
algorithm to prevent drug omissions and delays [21] using the equivalent dosages proposed
by Tomlinson et al. [22] (Table 1).
Drug Conversion Factor
Immediate release levodopa 1
Controlled release levodopa 0.75
Entacapone* LD 0.33
Tolcapone* LD 0.5
Duodopa® 1.11
Pramipexole 100
Ropirinole 20
Rotigotine 30
Selegiline 10
Rasagiline 100
Amantadine 1
Apomorphine 10
Bromocriptine 10
*To calculate the total LED for COMT inhibitors (entacapone and tolcapone), the total levodopa (including controlled
release levodopa if COMT inhibitor is given simultaneously) amount should be calculated and then multiplied by the
appropriate value. For Stalevo®, the levodopa and COMT inhibitor should be split and calculated separately.
Table 1. Conversion factors to calculate levodopa equivalent dose (LED) adapted from ref [22].
In Figure 2, we provide an example for how the algorithm could be applied to prevent an
omission.
Nevertheless, if a PD patient must be kept Nil per Os (NPO), thus interfering with the pa‐
tient’s unique schedule of medication administration, a neurologist or Neurology team should
oversee the medication regimen change to avoid complications, using alternatives such as
intradermal rotigotin or subcutaneous apomorphine [23]. In the same study mentioned
above, 88% of admissions (227/257) were some dosage was not administered because of
“oral intolerance” or NPO status, no alternative drug was used. In four hospitals, no patient
received an alternative drug.
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Paraphrasing Magdalinou “PD medications should be regarded as important as insulin is for
diabetics” [10]. We completely agree. It is about time we take the appropriate measures to
minimize the problem.
Figure 2. Theoretical example of the algorithm application.
3. Central-acting antidopaminergic administration
Not only anti-PD drugs like levodopa should be taken into account when patients are admitted
to hospital. Some drugs are considered inappropriate in PD, since in the same way as
dopaminergic drug omissions, they can worsen motor functioning. This is the case with
central-acting dopamine antagonists.
While PD has traditionally been considered a motor system disorder, it is nowadays recog‐
nized to be a complex condition with diverse clinical features that include neuropsychiatric
and many other non-motor symptoms. Researchers are increasingly attending to and charac‐
terizing the non-motor symptoms of the disease such as depression, apathy, dementia and
psychosis.
3.1. Psychosis
Although patients with both parkinsonism and dementia commonly experience spontane‐
ous visual hallucinations, delusions and paranoia even in the absence of medications for the
motor dysfunction, the introduction of dopaminergic therapies frequently triggers or exacer‐
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bates the underlying propensity to psychosis in patients who have PD dementia. Correcta‐
ble infectious, toxic and metabolic etiologies (delirium) must be ruled out. If symptoms persist,
antiparkinsonian drugs should be slowly reduced, which usually results in a worsening of the
parkinsonian features that may be poorly tolerated. When these measures fail, therapy with
antipsychotic drugs might be needed [24–26].
Almost all antipsychotic drugs are known to produce PD exacerbation. Clozapine is the only
antipsychotic that has level I evidence to support its use in these patients [26]. Nevertheless,
quetiapine is frequently considered the first-line choice for treating psychotic symptoms in
PD (e.g., by the American Academy of Neurology), and it is usually reported as the most
frequently used [27]. The rest of antipsychotic agents, especially high potency drugs such as
haloperidol, are considered inappropriate in PD. In the same line, and as PD disease usually
affects old people (aged >65 years), the most frequently used tools employing explicit criteria
to detect potentially inappropriate prescriptions in older patients (Beers and STOPP-START)
criteria consider inappropriate all antipsychotics other than clozapine or quetiapine [28, 29].
We were surprised to find aripiprazole included as one of the least-problematic antipsychot‐
ic therapies for PD psychosis, at the same level as quetiapine and clozapine in the last version
of the Beers criteria. Despite its promising receptorial profile, preliminary experience with
aripiprazole shows a discouraging safety and efficacy profile in individuals with PD, who
represent the most stringent test of a drug’s potential for inducing parkinsonism. In this sense,
severe worsening of motor function has been reported, with one individual requiring
parenteral fluid substitution and another requiring nasogastric tube feeding [30]. In light of
the evidence mentioned above and considering the widespread use of the Beers criteria, we
believe including aripiprazole in the same category as clozapine and quetiapine for the
treatment of PD psychosis could do more harm than good [31].
Delirium, or acute confusional state, has been reported as very prevalent in PD inpatients, and
being involved in as many as a quarter of admissions [32, 33]. Dementia, which mainly affects
patients with advanced disease, constitutes a known risk factor for delirium. As pointed out
before, correctable infectious, toxic and metabolic etiologies should be ruled out before
considering antipsychotic treatment. Sadly, many times haloperidol is prescribed in our setting
to treat “agitation” in patients, either with PD or not.
3.2. Nausea and vomiting
Nausea and vomiting, which are common adverse effects of anti-PD medications (levodopa
and dopamine agonists), might require treatment with antiemetic drugs. Metoclopramide and
other centrally acting antiemetics are contraindicated in PD patients because they block
dopaminergic receptors in the nigrostriatal area, generating deleterious motor effects [26].
Some cases of metoclopramide-associated encephalopathy have even been reported [34, 35].
On the other side, domperidone has traditionally been considered as the gold standard, since
it does not readily cross the blood-brain barrier [26]. Nevertheless, its cardiac safety has been
put into question recently [36, 37].
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3.3. Hiccups
Hiccups are starting to be considered one more “non-motor” symptom of PD [38]. A study
evaluated the presence of hiccups in 90 PD patients and 100 age-matched controls, finding that
hiccups were more frequent in PD patients than in healthy controls. Interestingly, chlorpro‐
mazine (a “typical” antipsychotic formally contraindicated in PD) is usually used to treat
incoercible hiccups.
Whatever the reason for they were prescribed, centrally acting antidopaminergic drugs have
shown to generate deleterious effects in PD inpatients. The study carried out in Florida, which
was mentioned above [16], showed that contraindicated dopamine blocking agent’s
administration (which occurred in 23% of the cases) was significantly related to an increased
length of stay (8,2 vs 3,5 days)(Figure 3).
In conclusion, avoiding drugs known to exacerbate motor symptoms should be a priority.
Clozapine and quetiapine should be preferred among antipsychotics [9]. Regarding antiemet‐
ic use, low dose of domperidone seems reasonable.
Figure 3. Deleterous effects of antidopaminergics in Parkinson’s Disease.
4. Anticholinergic burden in PD inpatients
Anticholinergic toxicity is often the consequence of the cumulative burden of multiple
medications and metabolites rather than a result of the action of a single drug [39]. Thus,
treatment of comorbidities (e.g., bladder control problems, psychosis and depression) with
drugs with anticholinergic properties could contribute to aggravate the problem. Indeed, the
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most frequently used tools employing explicit criteria to detect potentially inappropriate
prescriptions in the elderly dedicate a specific section to anticholinergic drug use [28, 29].
Drugs with anticholinergic activity can lead to adverse reactions in the central nervous system
such as cognitive disturbance, especially in elderly people, so extreme caution is required when
using them in people with previously known cognitive dysfunction. In this sense, dementia
has a prevalence of 80–90% in the most advanced phases of PD [25, 27]. Besides, using
anticholinergics in patients on cholinesterase inhibitors (which are the treatment of demen‐
tia in PD) could limit their beneficial effect due to a pharmacodynamic interaction [28]. Further,
peripheral anticholinergic side effects, including tachycardia, constipation, urinary retention
and blurred vision, should also be considered because they may lead to serious morbidity,
especially in PD patients who frequently present with autonomic dysfunction.
Anticholinergics like trihexyphenidil, biperiden and benztropine have remained one of the
available antiparkinsonian drugs in the antiparkinsonian armamentarium. But considering
the potential risks, it is easier to understand why nowadays anticholinergics are hardly used
to treat PD, with the exception of severe tremor in younger patients without cognitive
dysfunction [40].
In a recent study on PD patients admitted to acute care hospitals in the Basque Health care
system, we found that anticholinergic burden was relatively high and arose from drugs
prescribed to treat non-motor symptoms and other comorbidities rather than the motor
symptoms of the disease [41]. Interestingly, the total number of drugs and cholinesterase drug
prescriptions were independently associated with anticholinergic drug use whatever the scale
administered (the study was performed using four different scales to measure anticholiner‐
gic burden).
As described above, anticholinergic toxicity is often the result of the cumulative burden of
multiple medications. For that purpose, many drug lists have been designed to measure the
total anticholinergic burden, but they substantially differ both in which drugs are included
and in the anticholinergic activity assigned to each compound [42]. Moreover, some drugs
with undoubted anticholinergic properties (such as biperiden, solifenacin, trospium and
fesoterodine) that were prescribed to some inpatients had to be discarded in this study as these
compounds do not appear in any of the published lists [43], including the list providing a
systematic review of the literature, which in our opinion is the most complete so far [44]. Thus,
developing a credible, consistent, periodically updated screening tool to measure anticholi‐
nergic burden should be a priority, in order to avoid confusion in the future [45].
In definitive, potential anticholinergic toxicity should be kept in mind by clinicians, especial‐
ly in those elderly patients suffering from cognitive dysfunction. Alternative drugs that lack
anticholinergic activity should be used when possible.
In conclusion, all professionals involved in healthcare should pay attention to the specific
pharmacotherapeutic challenges faced by PD patients in acute care hospitals. Efforts should
be made to administer each levodopa dose on time. Drugs with central antidopaminergic
activity like haloperidol and metoclopramide should be avoided. And finally, using alterna‐
tive drugs without antimuscarinic properties when possible seems a reasonable option.
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